Logotipo do repositório
 

Publicação:
VNTR Polymorphism in Intron 4 of the eNOS Gene and the Risk of Gastrointestinal Bleeding: A Case-control Study

dc.contributor.authorForgerini, Marcela [UNESP]
dc.contributor.authorUrbano, Gustavo
dc.contributor.authorde Nadai, Tales Rubens
dc.contributor.authorZanelli, Cleslei Fernando [UNESP]
dc.contributor.authorValentini, Sandro Roberto [UNESP]
dc.contributor.authorMastroianni, Patrícia de Carvalho [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.date.accessioned2023-03-01T20:49:45Z
dc.date.available2023-03-01T20:49:45Z
dc.date.issued2022-06-01
dc.description.abstractBackground & Aims: Considering the lack of knowledge regarding the influence of the variable number of repeats of 27 pb in intron 4 (4b/4a VNTR-rs61722009) of the endothelial nitric oxide synthase (eNOS) on the drug response, we assessed the influence of this polymorphism for the risk of upper gastrointestinal bleeding (UGIB). Methods: A case-control study, including 200 cases and 706 controls, was conducted in a Brazilian hospital complex. Cases were participants with UGIB diagnosis. Controls were participants admitted to surgical procedures not related to gastrointestinal problems. The 4b/4a VNTR was determined through polymerase chain reaction followed by fragment analysis. Conditional logistic regression models were designed. The additive interaction between the presence of the 4b/4a VNTR variant and the use of low-dose aspirin (LDA) and nonsteroidal anti-inflammatory drugs (NSAIDs) was calculated by fitting the Cox regression model through the parameters of Synergism index (S) and Relative Excess Risk Due To Interaction (RERI). Results: The presence of the 4b/4a VNTR variant did not increase the risk of UGIB: carriers of the 4a/4a genotype (OR=0.37, 95%CI: 0.09-1.45) and of the variant allele “4a” (OR=0.91, 95%CI: 0.55-1.51). The risk of UGIB in LDA users carriers of the wild genotype (OR=4.96, 95%CI: 2.04-2.06) and the variant allele “4a” (OR=3.49, 95%CI: 1.18-10.38) is similar, as well as for NSAID users carriers of the wild genotype (OR=5.73, 95%CI: 2.61-12.60) and variant allele “4a” (OR=5.51, 95%CI: 1.42-15.82). No additive interaction was identified between the presence of the genetic variant and the use of LDA [RERI:-1.44 (95%CI:-6.02–3.14; S: 0.63 (95%CI:-1.97–1.15)] and NSAIDs [RERI:-0.13 (95%CI:-6.79–6.53; S: 0.97 (95%CI:-0.23–4.19)] on the UGIB risk. Conclusion: Our data suggests that there is no increase in the magnitude of UGIB risk in LDA and NSAIDs users’ carrying the variant allele “4a”.en
dc.description.affiliationDepartment of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationDepartment of Surgery School of Medicine University of São Paulo
dc.description.affiliationDepartment of Public Health Bauru School of Dentistry University of São Paulo (USP)
dc.description.affiliationDepartment of Biological Sciences School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationUnespDepartment of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationUnespDepartment of Biological Sciences School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.sponsorshipUniversidade Estadual Paulista
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipIdCAPES: 001
dc.description.sponsorshipIdFAPESP: 2017/24193-3
dc.description.sponsorshipIdFAPESP: 2018/07501-9
dc.description.sponsorshipIdCNPq: 401060/2014-4
dc.format.extent176-183
dc.identifierhttp://dx.doi.org/10.15403/JGLD-4226
dc.identifier.citationJournal of Gastrointestinal and Liver Diseases, v. 31, n. 2, p. 176-183, 2022.
dc.identifier.doi10.15403/JGLD-4226
dc.identifier.issn1841-8724
dc.identifier.scopus2-s2.0-85131903635
dc.identifier.urihttp://hdl.handle.net/11449/241162
dc.language.isoeng
dc.relation.ispartofJournal of Gastrointestinal and Liver Diseases
dc.sourceScopus
dc.subjectaspirin
dc.subjectgastrointestinal bleeding
dc.subjectnonsteroidal anti-inflammatory drugs
dc.subjectNSAIDs
dc.subjectpeptic ulcer hemorrhage
dc.subjecttandem repeat sequences
dc.subjectUGIB
dc.subjectVNTR Sequences
dc.titleVNTR Polymorphism in Intron 4 of the eNOS Gene and the Risk of Gastrointestinal Bleeding: A Case-control Studyen
dc.typeArtigopt
dspace.entity.typePublication
relation.isDepartmentOfPublication5004bcab-94af-4939-b980-091ae9d0a19e
relation.isDepartmentOfPublicatione214da1b-9929-4ae9-b8fd-655e9bfeda4b
relation.isDepartmentOfPublication.latestForDiscovery5004bcab-94af-4939-b980-091ae9d0a19e
unesp.departmentCiências Biológicas - FCFpt
unesp.departmentFármacos e Medicamentos - FCFpt

Arquivos